Apertura Gene Therapy is a pioneering brand at the forefront of next-generation gene therapies. With a focus on vector biology and protein engineering, Apertura is advancing genetic medicines through their high-throughput platforms. They aim to treat debilitating diseases with limited treatment options, expanding the promise of gene therapy to a broader set of conditions.

Apertura Gene Therapy stands apart with its unique approach to developing genetic medicines. By simultaneously engineering AAV capsids, regulatory elements, and payloads, they strive to overcome the current limitations of AAV gene therapy. Issues related to cellular access, gene expression, pre-existing immunity, and manufacturability have historically restricted the impact of gene therapy.

However, Apertura leverages recent advances in vector biology, protein engineering, machine learning, epigenetic profiling, next-generation sequencing, and DNA synthesis to overcome these limitations. The brand boasts a highly skilled multidisciplinary team that includes experts in vector engineering, gene regulation, machine learning, and the treatment of rare diseases. Their collective dedication and commitment drive breakthroughs in gene therapy across a wide range of genetic disorders.

Furthermore, Apertura Gene Therapy actively seeks partnerships to accelerate the impact of gene therapy. Collaborating with corporate and academic partners, patients, and disease foundations, they strive to maximize their reach and develop transformative gene therapies for more patients. Join Apertura Gene Therapy in their mission to revolutionize the future of gene therapy and improve the lives of those affected by genetic disorders